MIRALAC Calcium Carbonate Tablets Recalled for cGMP Deviations
Ultra Seal Corporation is recalling MIRALAC calcium carbonate 420mg tablets in mint flavor due to current Good Manufacturing Practice (cGMP) deviations. The recall affects 409,890 packets distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class II recall with no reported illnesses or injuries mentioned in the source text. The hazard is a manufacturing practice deviation without direct evidence of harm, placing it in the Moderate category per the severity rubric.
Plain-English summary
Ultra Seal Corporation is recalling MIRALAC (calcium carbonate 420mg) tablets in mint flavor, sold in 2-count packets and distributed by Honeywell Safety Products USA. The recall was initiated on January 24, 2022, due to deviations from current Good Manufacturing Practice (cGMP) standards.
The affected product is Lot #AK9486 with an expiration date of February 2022. Approximately 409,890 packets were distributed nationwide within the United States.
This is a voluntary recall initiated by the firm. The U.S. Food and Drug Administration classified this as a Class II recall on January 31, 2022. The recall was terminated on October 16, 2023.
Consumers who have purchased this product should discontinue use and may contact the manufacturer for further instructions.
The recalled product
- Product
- MIRALAC (calcium carbonate 420mg) tablets, Mint Flavor, 2-count packets, Dist. by Honeywell Safety Products USA, Smithfield, RI 02917
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cgmp-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AK9486
- Exp. Date 02/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27